Elevated PRAME expression: What does this mean for treatment of head and neck squamous cell carcinoma?

Biomarkers in Medicine

Volumn 7, Issue 4, 2013, Pages 575-578

  Szczepanski, Miroslaw J ^a,b   Whiteside, Theresa L ^c,d  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

chemoprevention; head and neck squamous cell cancer; HNSCC; PRAME; PRAME targeted immunotherapy; retinoic acid

Indexed keywords

ALPHA TOCOPHEROL; CANCER VACCINE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ISOTRETINOIN; PLACEBO; PROTEIN P53; PROTEIN PRAME; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR BETA; RETINOID; RETINOID X RECEPTOR; RETINOL; RETINOL PALMITATE; SELENIUM; SMALL INTERFERING RNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; ERYTHROPLASIA; GENE SILENCING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LEUKOPLAKIA; LOW DRUG DOSE; NOTE; PROGNOSIS; PROTEIN EXPRESSION; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RETINOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84881305125     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.68     Document Type: Note

References (23)

1. Mathers CC, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442 (2006
2. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N. Engl. J. Med. 345(26), 1890-1900 (2001
3. Langer CC. Exploring biomarkers in head and neck cancer. Cancer 118(16), 3882-3892 (2012
4. Calli C, Calli A, Pinar E, Oncel S, Tatar B. Prognostic significance of p63, p53 and ki67 expression in laryngeal basaloid squamous cell carcinomas. B-ENT 7(1), 37-42 (2011
5. Ikeda H, Lethé B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6(2), 199-208 (1997
6. Tanaka N, Wang YH, Shiseki M, Takanashi M, Motoji T. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk. Res. 35(9), 1219-1225 (2011
7. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122(6), 835-847 (2005
8. Epping MM, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res. 66(22), 10639-10642 (2006
9. Schantz SS. Chemoprevention strategies: The relevance of premalignant and malignant lesions of the upper aerodigestive tract. J. Cell. Biochem. Suppl. 17F, 18-26 (1993
10. Lotan R, Xu XC, Lippman SM et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med. 332(21), 1405-1410 (1995
11. Feng L, Wang Z. Clinical trials in chemoprevention of head and neck cancers. Rev. Recent Clin. Trials 7(3), 249-254 (2012
12. Siddikuzzaman, Guruvayoorappan C, Berlin Grace VM. All trans retinoic acid and cancer. Immunopharmacol. Immunotoxicol. 33(2), 241-249 (2011
13. Li RJ, Ying X, Zhang Y et al. All-Trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release 149(3), 281-291 (2011
14. Gudas LL, Wagner JA. Retinoids regulate stem cell differentiation. J. Cell Physiol. 226(2), 322-330 (2011
15. Szczepanski MJ, DeLeo AB, Luczak M et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol. 49(2), 144-151 (2013
16. Steele TO, Meyers A. Early detection of premalignant lesions and oral cancer. Otolaryngol. Clin. North Am. 44(1), 221-229, vii (2011
17. Rhee JJ, Khuri FF, Shin DM. Advances in chemoprevention of head and neck cancer. Oncologist 9(3), 302-311 (2004
18. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 40(1), 93-101 (1988
19. Brown G, Hughes P. Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk. Res. Treatment 2012, 939021 (2012
20. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: Long-Term follow-up. J. Natl. Cancer Inst. 86(2), 140-141 (1994
21. Bioley G, Guillaume P, Luescher I et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J. Immunother. 32(2), 161-168 (2009
22. Amir AL, van der Steen DM, van Loenen MM et al. PRAME-specific allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T cell receptor gene transfer. Clin. Cancer Res. 17(17), 5615-5625 (2011
23. Visus C, Wang Y, Lozano-Leon A et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin. Cancer Res. 17(19), 6174-6184 (2011